The mitochondrial permeability transition (PT) pore, also called the mitochondrial megachannel, is a multiprotein complex formed at the contact site between the mitochondrial inner and outer membranes, exactly the same location at which Bax, Bcl-2 and Bcl-X L are particularly abundant. The PT pore participates in the regulation of matrix Ca 2ϩ , pH, transmembrane potential and volume, and functions as a Ca 2ϩ -, voltage-, pH-and redox-gated channel with several levels of conductance and little, if any, ion selectivity. We have obtained three independent lines of evidence implicating the mitochondrial PT pore in apoptosis. First, in intact cells, apoptosis is accompanied by an early dissipation of the mitochondrial transmembrane potential, ⌬⌿ m . In several models of apoptosis, specific agents inhibiting the mitochondrial PT pore abolish this dissipation of the ⌬⌿ m and simultaneously prevent activation of downstream caspases and endonucleases, indicating that PT pore opening can be a critical event of the apoptotic process. Secondly, mitochondria are ratelimiting for caspase and nuclease activation in several cell-free systems of apoptosis. Isolated mitochondria release apoptogenic factors capable of activating pro-caspases or endonucleases upon opening of the mitochondrial megachannel in vitro. Thirdly, opening of the purified PT pore complex reconstituted into liposomes is inhibited by recombinant Bcl-2 or Bcl-X L , two apoptosis-inhibitory proteins that also prevent PT pore opening in cells and isolated mitochondria. Altogether, our results suggest that PT pore opening is sufficient and (mostly) necessary for triggering apoptosis. The implications of these findings are examined in the light of pharmacological interventions in apoptosis.
Introduction: mitochondria and permeability transition pores in apoptosis
Apoptosis may be defined as a cell-death process in which activation of catabolic processes and enzymes occurs prior to cytolysis, thereby facilitating the recognition, uptake and digestion of the apoptotic cell by dying neighbouring cells. It has long been assumed that the activation of endonucleases and specific proteases (caspases) would not only constitute a distinctive feature of apoptosis but also determine the decisive step (the 'decision to die' or 'commitment point') which distinguishes living from dying cells. It is now clear that, in most models of apoptosis, inhibition of nucleases and caspases does not prevent cytolysis, indicating that the 'decision to die' is taken before catabolic enzymes are activated and that the activation of such enzymes is a by-product of the cell-death process rather than a regulatory event [1] [2] [3] .
It has also long been assumed that mitochondria would not be involved in apoptosis. This notion was based on the observations that during apoptosis mitochondria do not undergo spectacular morphological changes, and that cells whose mitochondria lack mitochondrial DNA (Њ cells) maintain the capacity to undergo apoptosis. However, it has now become clear that mitochondria do exhibit major changes in their structure and function during apoptosis (for review see [1, [3] [4] [5] [6] [7] ). Moreover, mitochondria are now considered major players in the apoptotic process of mammalian cells, as demonstrated by our group [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] and as confirmed by others [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . Most if not all data are compatible with a (near-to) general mechanism of apoptosis in which three phases can be distinguished: (i) a pre-mitochondrial phase (induction phase) during which, depending on the apoptosis-inducing stimulus, a large variety of signal-transduction cascades or damage pathways can be activated; (ii) a mitochondrial phase (effector phase) during which mitochondrial membrane integrity is lost and the 'decision to die' is made; and (iii) a post-mitochondrial phase (degradation phase) during which soluble factors released by mitochondria activate catabolic hydrolases responsible for the apoptotic degradation of essential proteins and nuclear DNA.
Four major arguments suggest the involvement of mitochondria in apoptosis. First, kinetic studies indicate that mitochondria undergo major changes in membrane integrity before classical signs of apoptosis become manifest. Thus, a dissipation of the mitochondrial transmembrane potential (⌬⌿ m ) often precedes all other manifestations of apoptosis, including caspase activation [17] and subtle changes in plasma membrane lipid orientation [11] , redox potentials [8, 9] and ion homoeostasis [33, 34] . Moreover, a disruption of outer-mitochondrial-membrane barrier function with release of soluble intermembrane proteins into the cytosol is found during early apoptosis [10,14,23,25-28, 30,31] . Secondly, cell-free systems demonstrate that mitochondrial products are rate-limiting for the activation of caspases and endonucleases in cell extracts [10, 14, 23, 26, 27, 35] . Thirdly, pharmacological data indicate that certain drugs which stabilize mitochondrial membranes can prevent apoptosis [10, 13, 29] . Fourthly, extensive analysis of the proto-oncogene product Bcl-2 and of its apoptosis-inhibitory or apoptosis-inducing homologues has revealed that they act on mitochondria to regulate apoptosis [7, 10, 14, 19, [26] [27] [28] 36, 37] .
One of the mitochondrial structures involved in apoptosis control is the so-called permeability transition (PT) pore, also called the mitochondrial megachannel [38] [39] [40] . The PT pore is a dynamic multiprotein complex formed at the contact site between the inner and the outer mitochondrial membranes [41] [42] [43] . Although the exact composition of the PT pore complex is elusive, it is thought to involve proteins from the cytosol (hexokinase), the outer membrane (voltage-dependent anion channel), the inner membrane (the adenine nucleotide translocase, ANT) and the matrix (cyclophilin D), which interact to form the PT pore complex (PTPC) [19, 38, [40] [41] [42] [43] [44] [45] [46] [47] . The PT pore participates in the regulation of matrix Ca 2ϩ , pH, ⌬⌿ m and volume. Its opening/closing characteristics are influenced by multiple parameters: voltage (high voltage inhibits), the redox state of critical matrix thiols (reduction of thiols inhibits), the NAD(P)H 2 /NAD(P) ratio (reduction inhibits), the matrix pH (low pH inhibits), the concentrations of Ca 2ϩ and other divalent cations (matrix Ca 2ϩ opens but Mg 2ϩ closes), and the concentrations of ligands of hexokinase (glucose inhibits), creatine kinase (creatine inhibits) and the ANT (both ATP and ADP inhibit). The PT pore can provoke irreversible ⌬⌿ m dissipation at its high level of conductance (molecular cut-off Ϸ1500 Da) [38, 40, 44, 48] . Several PT pore inhibitors such as bongkrekic acid (a ligand of the ANT), cyclosporin A (a ligand of cyclophilin D), and chloromethyl-X-rosamine (a thiol-reactive agent distributing into the mitochondrial matrix) also prevent the loss of the ⌬⌿ m in several models of apoptosis [9, 49, 50] . Since cyclosporin A, for unknown reasons, is a transient inhibitor of PT [38] , its ⌬⌿ m -stabilizing effect is only revealed in experiments designed to last 120 min or less [9, 11, 33, 49] unless additional compounds such as aristolochic acid (a phospholipase A 2 inhibitor) are added [32] . In contrast, bongkrekic acid has a long-term protective effect on mitochondrial function [10, 11, 13, 15, 29] . Bongkrekic acid, chloromethyl-Xrosamine and the combination of cyclosporin A plus aristolochic acid can prevent all signs of apoptosis, at the mitochondrial as well as at the post-mitochondrial levels [10, 11, 13, 15, 29, [32] [33] [34] 50] . Conversely, PT pore opening induced by protoporphyrin IX (a ligand of the mitochondrial benzodiazepin receptor) causes disruption of the ⌬⌿ m , followed by full-blown apoptosis [13, 15, 18, 51] . Thus, opening of the megachannel is both sufficient and necessary for the induction of apoptosis, at least in those models which we have studied.
This chapter will concentrate on recent progress in this rapidly developing area. In particular, we will examine (i) which pro-apoptotic signaltransduction pathways can directly act on mitochondria; (ii) how Bcl-2 and Bax regulate apoptosis at the mitochondrial level; and (iii) how mitochondria can kill cells.
Pro-apoptotic signal-transduction pathways converging on mitochondria
The PTPC is formed at the inner/outer-membrane contact site; that is, at a site of metabolic co-ordination between the mitochondrial matrix, the intermembrane space and the cytosol [19, [41] [42] [43] . In accord with its submitochondrial localization and with its composite structure, the PTPC can be viewed as an integrator that senses metabolic perturbations [1, 3, 4, 38, 40, 44, 52] . In addition, it senses a variety of different pro-apoptotic signal-transduction pathways ( Figure 1 ).
Redox metabolism
Major shifts in cellular redox potentials due to an enhanced generation of reactive oxygen species (or a decrease in their detoxification), depletion of nonoxidized glutathione or depletion of NAD(P)H 2 can induce or facilitate PT pore opening [38, 40, 44] . Of note is that the mitochondrial megachannel possesses at least two redox-sensitive sites, one that is in equilibrium with mitochondrial matrix GSH, and one that can be directly activated by reactive oxygen species [53] . An enhanced generation of reactive oxygen species is not always the result of cellular damage; it can also result from overexpression of the pro-apoptotic anti-oncogene p53 [29] or from treatment of cells with the second messenger ceramide [54] . In addition to reactive oxygen species, nitric oxide can also act on mitochondria to open the PT pore [55, 56] .
Energy metabolism
The physiological ligands of the ANT (also called the ATP/ADP carrier) are ADP and ATP, which both function as endogenous inhibitors of PT [38, 40, 44, 57] . Their depletion therefore can facilitate PT pore opening. Similarly, a reduction of the ⌬⌿ m and matrix alkalization can also trigger PT pore opening [38, 40, 44] . Thus, uncoupling or inhibition of the respiratory chain (which leads to a decrease in ⌬⌿ m ) or inhibition of F 1 ATPase (which causes matrix alkalization) both favour opening of the PT pore.
Ceramide
Ceramide is produced in response to many different apoptosis-inducing triggers, including ligation of the Fas/Apo-1 or the tumour necrosis factor receptors, non-specific stress or cytotoxic drugs [58, 59] . Ceramide induces ⌬⌿ m dissipation when added to cells [9, 11, 17, 60, 61] but does not induce PT pore opening when added to isolated mitochondria [17, 60, 62] . Ceramide can also enhance the generation of reactive oxygen species by mitochondria, thereby depleting the pool of matrix GSH [62] . Cytosols from ceramidetreated cells are efficient inducers of PT in isolated mitochondria from untreated control cells. However, addition of ceramide to cytosols does not generate a PT-inducing activity [17, 60] . This suggests that, in intact cells, ceramide triggers the generation of a secondary messenger or metabolite which then accounts for the induction of PT. One possible candidate for such a ceramide metabolite is ganglioside 3 [61] .
Cytosolic calcium
Ca 2ϩ ions are among the most efficient inducers of PT. Via an electrophoretic mechanism, Ca 2ϩ ions are readily taken up via the mitochondrial Ca 2ϩ uniporter and act on the matrix site of PTPC to favour PT pore opening. Schematically, it appears that supraphysiological doses (ϾϾ10 M) of Ca 2ϩ suffice to induce PT, while lower doses facilitate the induction of PT by other stimuli [38, 40, 44] . Increases in free Ca 2ϩ concentration are also important comediators of apoptotic cell death. Indeed, the induction of thymocyte apoptosis by Ca 2ϩ can be prevented by the PT pore inhibitor cyclosporin A [63] . Moreover, Bcl-2 overexpression enhances the capacity of mitochondria to retain Ca 2ϩ before PT pore opening is triggered [64] .
Caspases
Ligation of some surface receptors can lead to the rapid activation of caspases (cysteine proteases cleaving after Asp residues), a family of proteases that are activated via specific proteolytic cleavage. This was first shown for the Fas/Apo-1/CD95 receptor, which recruits caspase-8 into the receptor complex and causes its activation upon interaction with the Fas/Apo-1/CD95 ligand. Caspase-8, as well as other caspases, can act on as-yet unknown substrates in the mitochondrial membrane, thereby inducing PT pore opening and the release of apoptogenic proteins [17, 19] . It appears plausible that primary caspase activation is not sufficient to trigger the apoptotic cascade and that the caspase-triggered release of mitochondrial apoptogenic factors is required in order to drive the apoptotic process [17, 25] .
Amphipathic peptides
A number of different amphipathic peptides have been shown to act on mitochondria to induce PT pore opening. This applies to mastoparan from wasp venom [65] and probably also to a series of other peptides which have been shown to affect mitochondrial membranes: the ␤-amyloid peptide accumulating in Alzheimer's disease [66] , the C-terminal domain of the Vpr peptide encoded by HIV-1 [67] , and the reaper peptide, which is involved in developmental cell death of the fruit fly [68] . In addition, several BH3-only peptides from the Bcl-2 family have been found to act on mitochondria and to increase their membrane permeability [69] .
In conclusion, it appears that several important pro-apoptotic pathways can converge on mitochondria and provoke opening of the PT pore.
How Bcl-2 and Bax regulate apoptosis at the mitochondrial level
Bcl-2 belongs to a growing family of proteins which can either inhibit (Bcl-2, Bcl-X L , Bcl-2w, etc.) or favour (Bax, Bcl-X S , Bak, etc.) apoptosis [6, 70] . The hydrophobic C terminus of Bcl-2 incorporates into the outer mitochondrial membrane, whereas the N terminus faces the cytosol. Bcl-2 exhibits a scattered distribution in the proximity of the inner/outer-membrane contact site [71] . At least in some experimental models, Bcl-2 exerts its apoptosisinhibitory effect only if it is present in the mitochondrion, rather than in other locations [72] [73] [74] [75] . Bcl-2 prevents signs of PT pore opening, such as ⌬⌿ m dissipation in cells [8, 9, 16, 76] , cytoplasts (cells lacking nuclei) [11, 16] and isolated mitochondria [10, 14, 15, 50] . Moreover, it prevents the mitochondrial release of apoptogenic proteins [10, 14, 26, 27] , the mitochondrial hypergeneration of reactive oxygen species [9] , the oxidation of the inner-membrane constituent cardiolipin [9] , and the release of small molecules such as Ca 2ϩ from the mitochondrial matrix [77] .
Bcl-2 overexpression augments the resistance of purified mitochondria to undergo PT pore opening in response to a number of different agents, including atractyloside, a substance that specifically affects the ANT. Bcl-2 also prevents ⌬⌿m disruption induced by t-butylhydroperoxide, low doses of Ca 2ϩ and low doses of protoporphyrin IX [10, 14, 15] . In addition to its ⌬⌿ m -stabilizing effect, Bcl-2 causes the retention of intermembrane proteins in mitochondria exposed to these agents [10, 14, 17] or to cytosols from ceramidetreated cells [17, 60] , cytosols from dying frog oocytes [27] , mild osmotic shock [26] or the amphipathic peptide reaper [68] . In contrast, recombinant Bax protein can induce ⌬⌿ m dissipation and cytochrome c release [78] when added to isolated mitochondria. This finding has been confirmed in mammalian and yeast cells transfected with Bax [24, 32, 79, 80] , suggesting that Bax acts to desta-bilize mitochondrial membrane function. All these Bax effects are inhibited by the PT pore inhibitor cyclosporin A, both in vitro and in vivo [32, 78, 81] , indicating that Bax acts via the PT pore.
We have recently purified complexes of hexokinase-associated proteins from the brain, which we have incorporated into liposomes to re-establish the function of the PT pore in vitro [19, 20] . Such PTPC liposomes can be exposed to different inducers of PT pore opening that cause an increase in membrane permeability (Figure 2 ). This can be measured by monitoring the release of small radioactive molecules (e.g. [ 3 H]glucose) from the liposomal lumen or by measuring the retention of the amphophilic cationic fluorochrome DiOC 6 (3) [19, 20, 81, 82] . Biochemical and functional data indicate that the PTPC enriched from brain homogenates contains the pro-apoptotic Bcl-2 homologue Bax (but no or little Bcl-2 and Bcl-X L ), in addition to proteins previously suggested to participate in the regulation of PT (ANT, voltage-dependent anion channel, cyclophilin D and hexokinase) [19] . Using a number of different inducers and inhibitors of PT, we found an approximate functional equivalence between the natural (mitochondrial) PT pore and the reconstituted (liposomal) PTPC with regard to the way in which it regulates membrane permeability. The functional Figure 2 The purified PTPC and its regulation by proteins from the Bcl-2 family. Membrane hexokinase-associated protein complexes from the rat brain are incorporated into phosphatidylcholine/cholesterol liposomes. The capacity of retaining the fluorochrome DiOC 6 (3) after stimulation with different inducers of PT pore opening is assessed using a flow-cytometric approach [19, 20] . Incorporation of recombinant Bcl-2 or Bcl-X L prevents DiOC 6 (3) release induced by a number of different agents that act to induce PT in control liposomes lacking Bcl-2 or Bcl-X L . Mutant Bcl-2 proteins Bcl-2(Gly145Ala) and Bcl-2⌬␣5/6 (⌬143-184) do not have this effect. Moreover, immunodepletion of Bax, which co-purifies with PTPC, abolishes the response to the ANT ligand atractyloside. Similarly, purification of PTPC from Bax knock-out mice yields a complex which does not respond to atractyloside. t-BHP, t-butylhydroperoxide.
exploration of PTPCs suggests that it contains functionally interconnected sites of interaction with bongkrekic acid and atractyloside (two ligands of the ANT and perhaps other members of the mitochondrial carrier family), cyclosporin A and N-methyl-4-Val-cyclosporin A (two ligands of cyclophilin D), diamide and monochlorobimane (which act on thiol residues) and Ca 2ϩ , as well as with recombinant caspases, for which the exact substrates remain to be defined [19] .
In an attempt to identify the molecules actually involved in pore formation, we immunodepleted Bax from the PTPC prior to reconstitution into liposomes. Such Bax-deficient PT pore liposomes fail to release the fluorochrome DiOC 6 (3) upon exposure to the ANT ligand atractyloside, whereas in control experiments atractyloside functions on sham-immunodepleted liposomes [81] (Figure 2 ). Recombinant Bcl-2 and Bcl-X L proteins incorporated into liposomes have an inhibitory effect on PT. The presence of Bcl-X L or Bcl-2 protected against the DiOC 6 (3) release induced by atractyloside, tert-butylhydroperoxide, as well as low doses of Ca 2ϩ and caspases [19] . A Bcl-2 deletion mutant lacking a putative channel-forming domain corresponding to the ␣5 and ␣6 helices, Bcl-2⌬␣5/6, which has lost its anti-apoptotic function [83] , fails to prevent liposomal transmembrane potential (⌬⌿ L ) disruption [19] . In addition, a Bcl-2 point mutant in the BH1 region, Bcl-2(Gly145Ala), which does not interact with Bax and does not protect against apoptosis [84] , has no inhibitory effect on the liposomes containing PTPCs [19] .
Altogether, these data indicate that Bcl-2-like proteins and PT pores are functionally and molecularly interwoven. Multiple physiological effectors, as well as the relative level of Bax-and Bcl-2-like proteins, regulate the propensity of the PT pore to open or close. The exact molecular mechanisms of this process are currently under intensive investigation.
How PT pore opening kills cells
If PT pore opening is the rate-limiting process of apoptosis and, at least in some cases, of necrosis (see Introduction), how does opening of the PT pore kill the cell? At the first level, opening of the PT pore must be expected to have dramatic metabolic consequences (Figure 3) . Thus, uncoupling of the respiratory chain leads to the cessation of ATP synthesis. Simultaneously, mitochondria start to hyperproduce superoxide anions, which can lead to the oxidation of mitochondrial products such as the inner-membrane component cardiolipin. PT also causes the depletion or oxidation of non-oxidized glutathione and of NAD(P) 2 [9, 18, 33, 85] . A disruption of Ca 2ϩ homoeostasis with an increase of cytosolic Ca 2ϩ levels appears to be secondary to the perturbed redox regulation [33] . Moreover, PT causes a cytosolic acidification [86] . Therefore, PT provokes several lethal perturbations in bioenergetic status, redox equilibrium and ion homoeostasis.
Opening of the PT pore causes an increase in mitochondrial matrix volume [38] . Since the surface of the outer mitochondrial membrane is much smaller than that of the inner membrane, opening of the PT pore thus causes the local mechanic disruption of the outer mitochondrial membrane with con-sequent release of soluble intermembrane proteins [87, 88] . This may explain how opening of the PT pore can provoke the release of solutes with molecular masses well above its molecular cut-off value of Ϸ1500 Da. Several proteins among those of the mitochondrial intermembrane released upon PT pore opening are endowed with the capacity to activate caspases or nucleases (Figure 3) .
First, mitochondria release cytochrome c (formerly called Apaf-2), which together with additional factors, namely Apaf-1 (the mammalian CED-4 homologue, which binds to the outer mitochondrial membrane), ATP and caspase-9, can proteolytically activate caspase-3, which in turn cleaves and activates DNA fragmentation factor, an endonuclease activator acting on the nucleus [23, 89, 90] . Cytochrome c intervenes in this system in its holo-form (that is, with the haem group attached), although its structure rather than its electron-acceptor function appears to be essential for its pro-apoptotic function [27] . Secondly, mitochondria release a ~50 kDa apoptosis-inducing factor (AIF). AIF suffices to activate endonucleases in isolated nuclei [10, 14, 17] . Depletion of cytochrome c does not affect its activation. However, addition of the caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (Z-VAD.fmk) can prevent its release and/or activation, suggesting that caspase activation is somehow relevant to the action of AIF. We have recently cloned AIF, which itself is not a caspase (S.A. Susin and G. Kroemer, unpublished work). Thirdly, mitochondrial intermembrane proteins contain a DNase activity [14] that is not identical to AIF (which has no intrinsic DNase activity). This DNase is non-specific and causes the degradation of naked doublestranded DNA, including that of supercoiled plasmid DNA. Fourthly, we have recently found that both pro-caspase-2 and pro-caspase-9 are contained in the mitochondrial intermembrane space. We have not found any evidence for the presence of other caspases in liver mitochondria. The caspase-2 and -9 zymogens are released upon PT pore opening and, once released, become proteolytically activated [91] . This can be achieved both in vitro, e.g. by addition of atractyloside to purified mitochondria, and in vivo, in the living cell [91] . Both caspases-2 and -9 have been considered to be apical in a number of different apoptosis-induction pathways [89, [92] [93] [94] [95] . The discovery that these caspases are contained in mitochondria [91] (and part of caspase-3 as well [96] ) underlines the strong functional link between PT and caspase activation. If PT is involved in both apoptosis and necrosis, what determines the difference between both modes of cell death? Apparently, the activation of caspases is crucial for this difference. Classical pro-apoptotic stimuli, such as glucocorticoids, etoposide, growth-factor withdrawal or overexpression of Bax, induce a necrotic, cytolytic type of death in the presence of the pleiotropic caspase inhibitor Z-VAD.fmk [18, 24, 97, 98] . Another determining factor for the 'decision' between apoptosis and necrosis is the intracellular ATP content. Manipulations tending to reduce cellular ATP levels favour the necrotic over the apoptotic mode of cell death, whereas an increased ATP supply (provided by glycolytic substrates) has the opposite effect [99, 100] .
The idea that PT can trigger both apoptosis (when caspases come into action) and necrosis (when such proteases fail to act) is compatible with the finding that many drugs induce necrosis at high doses and apoptosis at lower ('subnecrotic') doses. Induction of PT in a more smooth, protracted fashion allows for the activation and action of proteases before ATP depletion causes cell death. In contrast, when PT is induced in a massive, rapid fashion, heavily compromising cellular metabolism, necrosis occurs before apoptogenic proteases come into action. Of note is that it appears that several apoptosisinducing agents, including pro-oxidants and nitric oxide, can act on critical cysteine residues of caspases, thereby provoking their inactivation [101, 102] . This again would explain why low doses of these compounds (which induce PT) cause apoptosis, whereas high doses (which induce PT and inhibit caspases) cause necrosis. Thus, the intensity of the PT-inducing stimulus may determine which among the two major consequences of PT will dominate over the other: (i) a bioenergetic catastrophy culminating in cytolysis; or (ii) the activation/ action of apoptogenic caspases. The availability of pre-formed caspases (and their endogenous inhibitors?), as well as their post-translational modification (e.g. inactivation by oxidation or nitrosylation) [101, 102] , thus influences the propensity of cells to die from apoptosis versus necrosis. The relative apoptosis/necrosis susceptibility is also influenced by the ratio between glycolytic and respiratory ATP generation, which is differentially affected by the disruption of mitochondrial function. This would explain why lymphocytes (in which glycolytic ATP generation dominates) tend to undergo apoptosis, whereas neurons (in which respiratory ATP generation dominates) rather tend to undergo necrosis in response to stress.
Concluding remarks: the central role of the PT pore
As discussed above, the molecular mechanisms governing apoptosis at the pre-mitochondrial, mitochondrial and post-mitochondrial levels are increasingly becoming understood. An ever-accumulating mass of results points to the central role of the PT pore in death/life decision making. Information on the molecular composition of the PTPC is scant, although it becomes increasingly clear that it comprises both proteins involved in intermediate metabolism (e.g. ANT) and proteins involved in apoptosis control (e.g. Bax). If it turned out that the PT pore is truly central to the cell-death process, this would have farreaching consequences. In particular, the PTPC would constitute a privileged pharmacological target for cytoprotective and cytotoxic therapies. For cytoprotection, it would be useful to inhibit the PTPC, a strategy which would confer cellular resistance against a number of different adverse conditions. Conversely, drugs designed to open the PT pore would have broad cytotoxic effects. This may be an advantage in cancer therapy. The response of cells to different anti-cancer agents is frequently determined by signal-transducing events upstream of mitochondria. This is true for genotoxic events requiring activation of the p53 pathway [29, 103] or a series of chemotherapeutic agents involving signalling through the ceramide pathway [104] [105] [106] , through changes in cellular redox potentials [29] , or activation of the Fas/FasL system [105, 107] or analogous death receptors. Such agents thus elicit the genesis of secondary messengers (p53-induced genes, ceramide, caspase-8 activation through Fas etc.) which then affect mitochondria and induce cell death. On theoretical grounds, agents which directly affect mitochondria, and thus act on a more downstream level of apoptosis control, may be advantageous for treating cancers in which such signal-transducing systems are interrupted, e.g. those due to mutations of p53 or due to the expression of endogenous inhibitors of the Fas pathway.
In conclusion, it appears possible that PTPC will become an attractive pharmacological target. The elucidation of its (cell-type-specific?) composition, of its molecular dynamics, and of its detailed regulation should prepare us for the design of such agents in the near future. 
